Ask AI
ProCE Banner Activity

PROTAC ER Degraders in ER+/HER2- MBC Progressing After Endocrine Therapy: Emerging Mechanisms and Implications for Clinical Practice on the Horizon

Clinical Thought

This expert-led commentary summarizes the latest data and clinical pearls with PROTAC ER degraders and future application for ER+/HER2- MBC that has progressed after endocrine therapy.

Released: January 21, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc. and Arvinas.

Arvinas

Pfizer Inc.

Disclosure

Primary Author

Erika Hamilton, MD, FASCO

Chief Development Officer, Late Phase
Director, Breast Cancer Research Program
Sarah Cannon Research Institute (SCRI)
Nashville, Tennessee

Erika Hamilton, MD, FASCO: researcher (paid to institution): AbbVie, Accutar Biotechnology, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, BeOne, Bicycle, Biohaven, BioNTech, Compugen, Cullinan, Daiichi Sankyo, Dantari, Day One Biopharmaceuticals, Duality Biologics, Ellipses, Elucida Oncology, Exelixis, FujiFilm, Genmab, Gilead, H3 Biomedicine, Iambic Therapeutics, Immunogen, Inspirna, InventisBio, Jacobio, Jazz, K-Group Beta, Kind, Lilly, Loxo Oncology, Mabspace, Mabwell, Marengo, MediLink, Merck, Mersana, Novartis, Olema, Orinove, Orum, Pfizer, Pionyr, Prelude, Profound Bio, Regeneron, Relay, Rgenix, Roche/Genentech, SeaGen, Shattuck Labs, Simcha, Stemline, Sutro, Systimmune, Taiho, Tesaro, TheRas, Treadwell, Verastem, Xadcera, Zymeworks; consultant/advisor (paid to institution): Arvinas, AstraZeneca, BeOne, BioNTech, Boehringer Ingelheim, Boundless Bio, Bristol Myers Squibb, Circle, Daiichi Sankyo, Gilead, Halda, Incyclix, IQVIA, Janssen, Jazz, Jefferies, Johnson & Johnson, Lilly, Mersana, Novartis, Pfizer, Precede, Pyxis Oncology, Roche/Genentech, Samsung Bioepis, Shorla, Stemline, Tempus.